强生30.5亿美元收购肿瘤新贵Halda；胃癌双抗Ziihera三期数据积极；派格生物GLP-1R激动剂“维培那肽”获批上市

药财社11-18

●药闻快报▲关注药财社聚焦医药界▲1强生30.5亿美元收购肿瘤新贵Halda11月17日，路透社消息，强生宣布将以30.5亿美元现金收购私人控股的肿瘤疗法研发公司Halda Therapeutics。此次收购旨在进一步扩大强生在实体瘤及前列腺癌治疗领域的业务版图。Halda Therapeutics的核心候选药物HLD-0915目前处于早期至中期研发阶段，主要用于前列腺癌治疗。除核心管线外，该公司...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2584972959?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-18 20:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2584972959","market":"hk","top_or_hot":-1,"title":"强生30.5亿美元收购肿瘤新贵Halda；胃癌双抗Ziihera三期数据积极；派格生物GLP-1R激动剂“维培那肽”获批上市","media":"药财社","content":"<div>\n<p>●药闻快报▲关注药财社聚焦医药界▲1强生30.5亿美元收购肿瘤新贵Halda11月17日，路透社消息，强生宣布将以30.5亿美元现金收购私人控股的肿瘤疗法研发公司Halda Therapeutics。此次收购旨在进一步扩大强生在实体瘤及前列腺癌治疗领域的业务版图。Halda Therapeutics的核心候选药物HLD-0915目前处于早期至中期研发阶段，主要用于前列腺癌治疗。除核心管线外，该公司...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119001738a7024fb8&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生30.5亿美元收购肿瘤新贵Halda；胃癌双抗Ziihera三期数据积极；派格生物GLP-1R激动剂“维培那肽”获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生30.5亿美元收购肿瘤新贵Halda；胃癌双抗Ziihera三期数据积极；派格生物GLP-1R激动剂“维培那肽”获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-18 20:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119001738a7024fb8&s=b><strong>药财社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>●药闻快报▲关注药财社聚焦医药界▲1强生30.5亿美元收购肿瘤新贵Halda11月17日，路透社消息，强生宣布将以30.5亿美元现金收购私人控股的肿瘤疗法研发公司Halda Therapeutics。此次收购旨在进一步扩大强生在实体瘤及前列腺癌治疗领域的业务版图。Halda Therapeutics的核心候选药物HLD-0915目前处于早期至中期研发阶段，主要用于前列腺癌治疗。除核心管线外，该公司...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119001738a7024fb8&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119001738a7024fb8&s=b","article_id":"2584972959","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119001738a7024fb8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584972959","pubTimestamp":1763467253,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"此次收购旨在进一步扩大强生在实体瘤及前列腺癌治疗领域的业务版图。2胃癌双抗Ziihera三期数据积极Jazz Pharmaceuticals与Zymeworks今日联合宣布，其3期HERIZON-GEA-01研究取得积极主要结果。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","02565":"派格生物医药-B"},"translate_title":"Johnson & Johnson acquired oncology upstart Halda for US $3.05 billion; Phase III data of gastric cancer double antibody Ziihera are positive; Paige Biotech's GLP-1R agonist \"Vipenatide\" was approved for marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":0.9},"content_text":"●药闻快报▲关注药财社聚焦医药界▲1强生30.5亿美元收购肿瘤新贵Halda11月17日，路透社消息，强生宣布将以30.5亿美元现金收购私人控股的肿瘤疗法研发公司Halda Therapeutics。此次收购旨在进一步扩大强生在实体瘤及前列腺癌治疗领域的业务版图。Halda Therapeutics的核心候选药物HLD-0915目前处于早期至中期研发阶段，主要用于前列腺癌治疗。除核心管线外，该公司还布局了多款针对乳腺癌、肺癌及其他类型肿瘤的早期实验性疗法，其研发管线与强生的肿瘤治疗业务形成高度互补。2胃癌双抗Ziihera三期数据积极Jazz Pharmaceuticals与Zymeworks今日联合宣布，其3期HERIZON-GEA-01研究取得积极主要结果。该研究评估双特异性抗体Ziihera（zanidatamab）联合化疗，或在此基础上联合PD-1抑制剂Tevimbra（tislelizumab），用于一线治疗HER2阳性（HER2+）局部晚期或转移性胃食管腺癌，覆盖胃、胃食管交界与食管等部位的疗效与安全性。结果显示，Ziihera联合化疗相较活性对照药物联合化疗在无进展生存期（PFS）上取得具有临床意义且具有统计学显著性的提升。并在首次总生存期（OS）的中期分析中呈现具有临床意义、且接近统计学显著性的改善趋势。而Ziihera联用Tevimbra与化疗的三联方案，则在OS与PFS上均实现具有临床意义且统计学显著的提升。根据该试验结果，两家公司计划于2026年上半年提交补充生物制品许可申请（sBLA）。3派格生物GLP-1R激动剂“维培那肽”获批上市2025年11月14日，国家药品监督管理局（NMPA）官网显示，派格生物的维培那肽注射液（派达康®）上市许可申请已获批准，适应症为：用于改善成人2型糖尿病患者的血糖控制。维培那肽（PB-119）是一种聚乙二醇（PEG）化的艾塞那肽，可结合并激活体内 GLP-1 受体作为 GLP-1 受体激动剂，具有与天然人体 GLP-1 相似的生理作用，通过增强胰岛素的分泌，以葡萄糖依赖性的方式降低血糖水平，从而治疗 2 型糖尿病和肥胖症。已完成的临床试验结果显示，PB-119 具有快速、显著及持续的降糖作用，且兼具减重、改善整体脂质代谢谱及降低血压的效果，安全性和耐受性良好。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584972959","isCrawlerRequest":true}